Akorn, Inc. and Natco Pharma Limited Add Two Injectable Drug Products To API Supply and Margin Sharing Agreement

  
    
  
  
    
      Akorn, Inc. (AMEX: AKN) today announced that it has added two injectable 
      drug products to its API Supply and Margin Sharing Agreement with Natco 
      Pharma Limited (NSE: NATCOPHARM)(BSE: 524816).
    
    
      The two ANDA drug products are indicated for the prevention of nausea 
      and vomiting associated with cancer chemotherapy, and have a combined 
      current market size of approximately $360 million. Under the API Supply 
      and Margin Sharing Agreement that was in signed April 2006, Natco will 
      be responsible for the supply of active pharmaceutical ingredients for 
      both drug products, while Akorn will be responsible for the 
      manufacturing, regulatory submissions, marketing and distribution in the 
      hospital, clinic, and home healthcare markets in the United States and 
      Canada.
    
    
      Arthur S. Przybyl, Akorn’s President and Chief 
      Executive Officer stated, “We are excited to 
      expand our business partnership with Natco Pharma. These two products 
      will provide an excellent fit with our oncology product pipeline.”
    
    
      Rejeev Nannapaneni, Natco Pharma’s Chief 
      Operating Officer stated, “We are happy to 
      take our cooperation to four projects now. This deal structure will 
      enhance business opportunities in an increasingly competitive 
      environment.”
    
    
      About Akorn, Inc.
    
    
      Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. 
      Akorn has manufacturing facilities located in Decatur, Illinois and 
      Somerset, New Jersey and markets and distributes an extensive line of 
      hospital and ophthalmic pharmaceuticals. Additional information is 
      available at the Company’s website at www.akorn.com.
    
    
      About Natco Pharma Limited
    
    
      Natco Pharma Limited is an integrated pharmaceutical company based out 
      of Hyderabad, Andhra Pradesh, India. Natco has four manufacturing 
      facilities in and around Hyderabad. Among these, a large API facility 
      and a finished dosage pharmaceutical formulations facility are approved 
      by the U.S. FDA. Natco also has an independent Research Centre located 
      at Hyderabad which supports its manufacturing facilities. Additional 
      information is available at the Company’s 
      website at www.natcopharma.co.in.
    
    
      Materials in this press release may contain information that includes or 
      is based upon forward-looking statements within the meaning of the 
      Securities Litigation Reform Act of 1995. Forward-looking statements 
      give our expectations or forecasts of future events. You can identify 
      these statements by the fact that they do not relate strictly to 
      historical or current facts. They use words such as "anticipate," 
      "estimate," "expect," "project," "intend," "plan," "believe," and other 
      words and terms of similar meaning in connection with a discussion of 
      future operating or financial performance. In particular, these include 
      statements relating to future steps we may take, prospective products, 
      future performance or results of current and anticipated products, sales 
      efforts, expenses, the outcome of contingencies such as legal 
      proceedings, and financial results.
    
    
      Any or all of our forward-looking statements here or in other 
      publications may turn out to be wrong. They can be affected by 
      inaccurate assumptions or by known or unknown risks and uncertainties. 
      Many such factors will be important in determining our actual future 
      results. Consequently, no forward-looking statement can be guaranteed. 
      Our actual results may vary materially, and there are not guarantees 
      about the performance of our stock.
    
    
      Any forward-looking statements represent our expectations or forecasts 
      only as of the date they were made and should not be relied upon as 
      representing our expectations or forecasts as of any subsequent date. We 
      undertake no obligation to correct or update any forward-looking 
      statements, whether as a result of new information, future events or 
      otherwise, even if our expectations or forecasts change. You are 
      advised, however, to consult any further disclosures we make on related 
      subjects in our reports filed with the SEC. In particular, you should 
      read the discussion in the section entitled "Cautionary Statement 
      Regarding Forward-Looking Statements" in our most recent Annual Report 
      on Form 10-K, as it may be updated in subsequent reports filed with the 
      SEC. That discussion covers certain risks, uncertainties and possibly 
      inaccurate assumptions that could cause our actual results to differ 
      materially from expected and historical results. Other factors besides 
      those listed there could also adversely affect our results.
    
  
Akorn, Inc. (AMEX: AKN) today announced that it has added two
injectable drug products to its API Supply and Margin Sharing
Agreement with Natco Pharma Limited (NSE: NATCOPHARM)(BSE: 524816).

   The two ANDA drug products are indicated for the prevention of
nausea and vomiting associated with cancer chemotherapy, and have a
combined current market size of approximately $360 million. Under the
API Supply and Margin Sharing Agreement that was in signed April 2006,
Natco will be responsible for the supply of active pharmaceutical
ingredients for both drug products, while Akorn will be responsible
for the manufacturing, regulatory submissions, marketing and
distribution in the hospital, clinic, and home healthcare markets in
the United States and Canada.

   Arthur S. Przybyl, Akorn's President and Chief Executive Officer
stated, "We are excited to expand our business partnership with Natco
Pharma. These two products will provide an excellent fit with our
oncology product pipeline."

   Rejeev Nannapaneni, Natco Pharma's Chief Operating Officer stated,
"We are happy to take our cooperation to four projects now. This deal
structure will enhance business opportunities in an increasingly
competitive environment."

   About Akorn, Inc.

   Akorn, Inc. manufactures and markets sterile specialty
pharmaceuticals. Akorn has manufacturing facilities located in
Decatur, Illinois and Somerset, New Jersey and markets and distributes
an extensive line of hospital and ophthalmic pharmaceuticals.
Additional information is available at the Company's website at
www.akorn.com.

   About Natco Pharma Limited

   Natco Pharma Limited is an integrated pharmaceutical company based
out of Hyderabad, Andhra Pradesh, India. Natco has four manufacturing
facilities in and around Hyderabad. Among these, a large API facility
and a finished dosage pharmaceutical formulations facility are
approved by the U.S. FDA. Natco also has an independent Research
Centre located at Hyderabad which supports its manufacturing
facilities. Additional information is available at the Company's
website at www.natcopharma.co.in.

   Materials in this press release may contain information that
includes or is based upon forward-looking statements within the
meaning of the Securities Litigation Reform Act of 1995.
Forward-looking statements give our expectations or forecasts of
future events. You can identify these statements by the fact that they
do not relate strictly to historical or current facts. They use words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of similar meaning in
connection with a discussion of future operating or financial
performance. In particular, these include statements relating to
future steps we may take, prospective products, future performance or
results of current and anticipated products, sales efforts, expenses,
the outcome of contingencies such as legal proceedings, and financial
results.

   Any or all of our forward-looking statements here or in other
publications may turn out to be wrong. They can be affected by
inaccurate assumptions or by known or unknown risks and uncertainties.
Many such factors will be important in determining our actual future
results. Consequently, no forward-looking statement can be guaranteed.
Our actual results may vary materially, and there are not guarantees
about the performance of our stock.

   Any forward-looking statements represent our expectations or
forecasts only as of the date they were made and should not be relied
upon as representing our expectations or forecasts as of any
subsequent date. We undertake no obligation to correct or update any
forward-looking statements, whether as a result of new information,
future events or otherwise, even if our expectations or forecasts
change. You are advised, however, to consult any further disclosures
we make on related subjects in our reports filed with the SEC. In
particular, you should read the discussion in the section entitled
"Cautionary Statement Regarding Forward-Looking Statements" in our
most recent Annual Report on Form 10-K, as it may be updated in
subsequent reports filed with the SEC. That discussion covers certain
risks, uncertainties and possibly inaccurate assumptions that could
cause our actual results to differ materially from expected and
historical results. Other factors besides those listed there could
also adversely affect our results.